Study of Endovascular Treatment for Acute Ischemic Stroke Caused by Blockage in the M2 Segment of the Middle Cerebral Artery

What this Trial Is About

Researchers are evaluating the safety and effectiveness of endovascular therapy compared to medical therapy alone for treating acute ischemic stroke caused by blockage in the M2 segment of the middle cerebral artery. This study is a randomized, controlled trial with open-label treatment and blinded outcome assessment, aiming to improve functional outcomes after stroke. Participants are randomly assigned to receive either endovascular therapy alongside medical treatment or medical treatment alone. The intervention involves initiating endovascular therapy within 30 minutes of randomization. The study includes a 90-day follow-up period to assess recovery and safety outcomes. This trial is conducted after the therapy is already approved for market use. During the study, participants undergo assessments including the modified Rankin Scale to measure functional outcomes at 90 days, neurological evaluation with the NIH Stroke Scale at 48 hours, and imaging to monitor for brain bleeding. Quality of life questionnaires are also completed. Safety is closely monitored for events such as intracranial hemorrhage and death. The total participation time covers up to three months following randomization.

Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the M2 Segment of Middle Cerebral Artery